RxSight (RXST) Competitors

RxSight logo
$31.90 -0.29 (-0.90%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$31.16 -0.74 (-2.34%)
As of 02/12/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXST vs. NARI, NVST, PRCT, IRTC, WRBY, LIVN, ENOV, TMDX, NVCR, and TNDM

Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), TransMedics Group (TMDX), NovoCure (NVCR), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.

RxSight vs.

Inari Medical (NASDAQ:NARI) and RxSight (NASDAQ:RXST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.

Inari Medical presently has a consensus price target of $68.00, indicating a potential downside of 14.91%. RxSight has a consensus price target of $58.13, indicating a potential upside of 82.21%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than Inari Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inari Medical
0 Sell rating(s)
12 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
RxSight
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Inari Medical has a net margin of -13.68% compared to RxSight's net margin of -23.92%. Inari Medical's return on equity of -10.09% beat RxSight's return on equity.

Company Net Margins Return on Equity Return on Assets
Inari Medical-13.68% -10.09% -6.60%
RxSight -23.92%-14.00%-12.51%

Inari Medical has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Inari Medical has higher revenue and earnings than RxSight. Inari Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari Medical$574.50M8.14-$1.64M-$1.35-59.20
RxSight$89.08M14.43-$48.61M-$0.83-38.43

In the previous week, Inari Medical had 2 more articles in the media than RxSight. MarketBeat recorded 4 mentions for Inari Medical and 2 mentions for RxSight. RxSight's average media sentiment score of 1.81 beat Inari Medical's score of 0.19 indicating that RxSight is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inari Medical
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
RxSight
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Inari Medical received 19 more outperform votes than RxSight when rated by MarketBeat users. However, 68.12% of users gave RxSight an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.

CompanyUnderperformOutperform
Inari MedicalOutperform Votes
66
57.89%
Underperform Votes
48
42.11%
RxSightOutperform Votes
47
68.12%
Underperform Votes
22
31.88%

91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Inari Medical and RxSight tied by winning 9 of the 18 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXST vs. The Competition

MetricRxSightOphthalmic goods IndustryMedical SectorNASDAQ Exchange
Market Cap$1.29B$11.14B$5.65B$9.04B
Dividend YieldN/A1.63%5.31%4.00%
P/E Ratio-38.4336.6790.8219.28
Price / Sales14.434.961,051.1879.82
Price / CashN/A16.0746.0938.87
Price / Book7.143.195.135.00
Net Income-$48.61M$235.23M$113.24M$222.75M
7 Day Performance-4.97%-3.58%-0.68%-0.72%
1 Month Performance3.84%-1.82%5.21%4.19%
1 Year Performance-36.96%-3.61%25.35%21.73%

RxSight Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXST
RxSight
2.9422 of 5 stars
$31.90
-0.9%
$58.13
+82.2%
-37.2%$1.29B$89.08M-38.43220
NARI
Inari Medical
1.6458 of 5 stars
$79.86
+0.1%
$68.00
-14.9%
+37.8%$4.68B$493.63M-59.161,300
NVST
Envista
3.6219 of 5 stars
$21.24
0.0%
$20.21
-4.9%
-8.5%$3.66B$2.51B-3.2712,800Analyst Revision
PRCT
PROCEPT BioRobotics
3.4448 of 5 stars
$69.75
+0.3%
$97.86
+40.3%
+31.1%$3.64B$136.19M-35.77430Positive News
IRTC
iRhythm Technologies
0.9387 of 5 stars
$109.50
-0.5%
$108.45
-1.0%
-6.7%$3.43B$560.03M-22.532,000
WRBY
Warby Parker
2.4125 of 5 stars
$26.64
+1.0%
$21.77
-18.3%
+82.4%$2.71B$669.77M-98.683,491
LIVN
LivaNova
3.4747 of 5 stars
$48.51
+1.4%
$69.17
+42.6%
-6.0%$2.63B$1.15B115.502,900
ENOV
Enovis
3.3347 of 5 stars
$44.45
+1.0%
$65.86
+48.1%
-27.5%$2.53B$1.71B-20.306,550Short Interest ↓
Positive News
TMDX
TransMedics Group
4.2037 of 5 stars
$70.24
-3.3%
$122.70
+74.7%
-21.0%$2.36B$241.62M74.72210Short Interest ↑
NVCR
NovoCure
3.722 of 5 stars
$21.65
-2.7%
$32.67
+50.9%
+32.7%$2.34B$509.34M-15.461,453
TNDM
Tandem Diabetes Care
4.227 of 5 stars
$35.23
-2.4%
$53.81
+52.7%
+37.2%$2.31B$747.72M-18.252,400Positive News

Related Companies and Tools


This page (NASDAQ:RXST) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners